Detection and Analysis of EGFR and KRAS Mutations in the Patients with Lung Squamous Cell Carcinomas
10.3779/j.issn.1009-3419.2015.10.04
- VernacularTitle:肺鳞癌EGFR与KRAS基因突变状态分析
- Author:
ZHANG HUI
1
;
YANG XINJIE
;
QIN NA
;
LI XI
;
YANG HUIYI
;
NONG JINGYING
;
LV JIALIN
;
WU YUHUA
;
ZHANG QUAN
;
ZHANG XINYONG
;
WANG JINGHUI
;
SU DAN
;
ZHANG SHUCAI
Author Information
1. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所肿瘤内科
- Keywords:
Lung neoplasms;
Epidermal growth factor receptor;
KARS gene;
Mutation;
Squamous
- From:
Chinese Journal of Lung Cancer
2015;(10):621-625
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Activating mutations in epidermal growth factor receptor (EGFR) and KARS are important markers in non-small cell lung cancer. However, EGFR and KARS gene mutations in lung squamous cell carcinoma are rarely reported. hTe aim of this study was to analyze EGFR and KARS gene mutation rate and their relationship with clinical features in patients with lung squamous cell carcinomas. Methods A total of 139 patients undergoing treatment for na?ve lung squamous cell carcinomas with tumor tissue samples available for testing were recruited. EGFR and KARS mutation statuses of the tumor samples were detected using a mutant enriched liquid chip. Results Of the 139 cases of lung squamous cell carcinoma, EGFR mutations were detected in 25 cases (18%), KARS mutations were detected in 7 cases (5%), and the pres-ence of both EGFR and KARS mutations was detected in 1 case (0.7%). EGFR mutations occurred more otfen in females than in males (33.3%vs 16.5%) and in patients that never smoked than in those who smoke (29.6%vs 16.1%). However, the differ-ence did not reach statistical signiifcance (P>0.05). No signiifcant differences were observed in age, stage, and different biopsy type. KARS mutations occurred more otfen in males than in females (5.5%vs 0%), but the difference did not reach statistical signiifcance (P>0.05). No signiifcant differences were observed in age, stage, different biopsy type, and smoking status (P>0.05). Conclusion EGFR and KARS mutations were low in lung squamous cell carcinomas, and had no signiifcant correlation with clinical features. Before using tyrosine kinase inhibitor targeted therapy, EGFR and KARS mutations should be detected in pa-tients with lung squamous cell carcinomas.
